| Literature DB >> 31585413 |
Ken Maynard1,2,3, Melissa LoPresti1,2, Ionela Iacobas4,5,6, Peter Kan2, Sandi Lam1,2,3.
Abstract
Intracerebral arteriovenous malformations (AVMs) are high-flow collections of abnormal vessels and a common cause of pediatric intracranial hemorrhage. There are few treatment options available for AVMs not amenable to surgical resection, endovascular embolization, radiosurgery, or multimodality treatment. The authors sought to review the molecular and genetic pathways that have been implicated in the formation of AVMs, focusing on the possibility of medically targeting these pathways in the treatment of AVMs. In the novel case presented here, a pediatric patient who was diagnosed with an intracranial AVM unamenable to conventional treatments underwent alternative treatment with molecular pathway inhibitors.Entities:
Keywords: AKT = protein kinase b; AVM = arteriovenous malformation; ERK = extracellular signal–regulated kinase; MAPK = mitogen-activated protein kinase; MEK = mitogen-activated protein kinase kinase; PI3K = phosphatidylinositol 3-kinase; PLCϒ = phospholipase C ϒ; TIA = transient ischemic attack; VEGF = vascular endothelial growth factor; VEGFR = VEGF receptor; angiogenesis; arteriovenous malformations; mTOR = mammalian target of rapamycin; pediatric; vascular disorders; vascular genetics
Year: 2019 PMID: 31585413 DOI: 10.3171/2019.7.PEDS1976
Source DB: PubMed Journal: J Neurosurg Pediatr ISSN: 1933-0707 Impact factor: 2.375